Multiple biomarker strategies for risk stratification in heart failure

Clinica Chimica Acta

Volumn 443, Issue , 2015, Pages 120-125

  Bayes Genis, Antoni ^a,b   Ordonez Llanos, Jordi ^b,c  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Heart failure; Multimarkers; Risk stratification

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APELIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; GALECTIN 3; MYELOPEROXIDASE; TROPONIN I; TROPONIN T; URIC ACID; VASCULOTROPIN RECEPTOR 1;

ACUTE HEART FAILURE; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART FAILURE; HUMAN; NEW YORK HEART ASSOCIATION CLASS; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCORING SYSTEM; METABOLISM; RISK FACTOR;

BIOMARKERS; HEART FAILURE; HUMANS; RISK FACTORS;

EID: 84924260688     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.10.023     Document Type: Article

References (37)

1. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson P.A. ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29:2388-42.
2. Bouvy M.L., Heerdink E.R., Leufkens H.G., Hoes A.W. Predicting mortality in patients with heart failure: a pragmatic approach. Heart 2003, 89:605-609.
3. Levy W.C., Mozaffarian D., Linker D.T., et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006, 113:1424-1433.
4. Pocock S.J., Wang D., Pfeffer M.A., et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006, 27:65-75.
5. Braunwald E. Heart failure. J Am Coll Cardiol Heart Fail 2013, 1:1-2.
6. Pencina M.J., D'Agostino R.B. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004, 23:2109-2123.
7. Januzzi J.L., van Kimmenade R.R. Importance of rigorous evaluation in comparative biomarker studies. J Am Coll Cardiol 2014, 63:167-169.
8. Ahmad T., Fiuzat M., Pencina M.J., et al. Charting a roadmap for heart failure biomarker studies. JACC Heart Fail 2014, 2:477-488.
9. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000, 355:1126-1130.
10. Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P. Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.
11. Januzzi J.L., Camargo C.A., Anwaruddin S., et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005, 95:948-954.
12. Clerico A., Passino C., Franzini M., Emdin M. Cardiac biomarker testing in the clinical laboratory: where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. Clin Chim Acta 2015, 443:17-24.
13. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358:2148-2159.
14. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803-869.
15. Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Drazner M.H. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013, 128:e240-e327.
16. Januzzi J.L., van Kimmenade R.R., Lainchbury J., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006, 27:330-337.
17. Bayes-Genis A., Santalo-Bel M., Zapico-Muniz E., et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 2004, 6:301-308.
18. Taub P.R., Daniels L.B., Maisel A.S. Usefulness of B-type natriuretic peptide levels in predicting hemodynamic and clinical decompensation. Heart Fail Clin 2009, 5:169-175.
19. Cheng V., Kazanagra R., Garcia A., et al. A rapid bedside test for B-type peptide predicts treatment outcomes patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001, 37:386-391.
20. van Kimmenade R.R., Januzzi J.L., Ellinor P.T., et al. Utility of amino-terminal Pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006, 48:1217-1224.
21. Shah R.V., Truong Q.A., Gaggin H.K., Pfannkuche J., Hartmann O., Januzzi J.L. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 2012, 33:2197-2205.
22. Pascual-Figal D.A., Manzano-Fernández S., Boronat M., et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011, 13:718-725.
23. Zairis M.N., Tsiaousis G.Z., Georgilas A.T., et al. Multimarker strategy for the prediction of 31days cardiac death in patients with acutely decompensated chronic heart failure. Int J Cardiol 2010, 141:284-290.
24. Apple F.S. A new season for cardiac troponin assays: it's time to keep a scorecard. Clin Chem 2009, 55:1303-1306.
25. Lassus J., Gayat E., Mueller C., et al. GREAT-Network. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol 2013, 168:2186-2194.
26. Seronde M.F., Gayat E., Logeart D., et al. Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure. Int J Cardiol 2013, 168:3404-3411.
27. Maisel A., Mueller C., Nowak R., et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) Trial. J Am Coll Cardiol 2010, 55:2062-2076.
28. Maisel A., Xue Y., Shah K., et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ Heart Fail 2011, 4:613-620.
29. Eurlings L.W., Sanders-van Wijk S., van Kimmenade R., et al. Multimarker strategy for short-term risk assessment in patients with dyspnea in the emergency department. The MARKED (Multi mARKer Emergency Dyspnea)-Risk Score. J Am Coll Cardiol 2012, 60:1668-1677.
30. Gegenhuber A., Struck J., Dieplinger B., et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007, 13:42-49.
31. Ky B., French B., Levy W.C., Sweitzer N.K. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 2012, 5:183-190.
32. Lupon J., de Antonio M., Galán A., et al. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. Mayo Clin Proc 2013, 88:234-243.
33. Bayes-Genis A., de Antonio M., Galan A., et al. Combined use of high sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail 2012, 14:32-38.
34. de Antonio M., Lupon J., Galan A., Vila J., Urrutia A., Bayes-Genis A. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. Am Heart J 2012, 163:821-828.
35. Lupón J., de Antonio M., Vila J., et al. Development of a novel heart failure risk tool: the Barcelona bio-heart failure risk calculator (BCN bio-HF calculator). PLoS One 2014, 9:e85466.
36. Gaggin H.K., Szymonifka J., Bhardwaj A., et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail 2014, 2:65-72.
37. Januzzi J.L., Rehman S.U., Mohammed A.A., et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011, 58:1881-1889.